Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tecentriq + Avastin before curative resection for hepatocellular carcinoma
ACTRN12624001345572Phase 2Recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) and liver cancer (2 arms), sponsored by Western Sydney Local Health District. Primary endpoint: Efficacy of neoadjuvant atezolizumab plus bevacizumab compared with active surveillance. Started Oct 2025; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)liver cancer
Beyond the preview
Go deeper on ACTRN12624001345572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001345572.